LYN is a non-receptor Src family tyrosine kinase that functions as both a positive and negative regulator of immune signaling, depending on cellular context 1. Primarily, LYN transmits signals downstream of B-cell receptors, Fc receptors, and toll-like receptors, regulating B-cell differentiation, survival, and immune tolerance through phosphorylation of ITIMs that recruit inhibitory phosphatases 1. LYN also mediates hematopoietic responses to cytokines and growth factors, controlling cell proliferation, migration, and cytokine release across immune cell types 1. Beyond canonical immune functions, LYN exhibits context-dependent roles in disease pathogenesis. Enhanced LYN activity causes spontaneous progressive emphysema and lung adenocarcinoma through aberrant epithelial proliferation and endothelial activation, independent of myeloid inflammation 2. In chr8 lymphocytic leukemia, LYN overexpression in stromal fibroblasts programs a leukemia-supportive microenvironment by regulating c-JUN and thrombospondin-1 3. LYN genetic polymorphisms significantly increase thyroid cancer risk 4, while LYN/RUVBL1 complexes promote colorectal cancer metastasis through epigenetic regulation of arachidonic acid metabolism 5. Conversely, LYN activation maintains platelet quiescence in healthy conditions but is impaired in sickle cell disease, contributing to pathological platelet activation 6. In polycystic ovary syndrome, elevated LYN binding to CBL exacerbates insulin resistance and ovarian dysfunction 7, while LYN inhibition in macrophages promotes anti-inflammatory phenotypes in atherosclerosis 8. These findings establish LYN as a critical node in immune homeostasis with broad implications for cancer and metabolic disease.